Cantor Fitzgerald Forecasts STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Stoke Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will earn ($2.40) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million.

A number of other research analysts also recently issued reports on STOK. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target for the company. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $10.02 on Wednesday. The stock has a 50-day simple moving average of $11.33 and a two-hundred day simple moving average of $12.85. The firm has a market capitalization of $530.76 million, a PE ratio of -4.77 and a beta of 0.95. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new position in shares of Stoke Therapeutics in the 3rd quarter worth approximately $160,000. The Manufacturers Life Insurance Company boosted its stake in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. purchased a new position in Stoke Therapeutics during the third quarter worth $192,000. Profund Advisors LLC bought a new position in Stoke Therapeutics during the second quarter valued at $201,000. Finally, Rhumbline Advisers raised its stake in shares of Stoke Therapeutics by 14.3% in the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock valued at $647,000 after acquiring an additional 5,990 shares during the period.

Insider Buying and Selling

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now owns 61,885 shares in the company, valued at $803,886.15. This trade represents a 9.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the sale, the general counsel now owns 21,476 shares in the company, valued at approximately $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,849 shares of company stock worth $809,421. Corporate insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.